ADLIB
Live / Registered — Registered — partial invalidation of extension of protection (as of 10 Jun 2023)
What this means for you
Registered since 14 Feb 2017. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 79169309
- Registration number
- 5139363
- Mark type
- Stylized text
- Filed
- 28 Apr 2015
- Published for opposition
- 29 Nov 2016
- Registered
- 14 Feb 2017
- Attorney of record
- Jeffrey H. Handelsman
Goods and services
- Class 005 — Pharmaceuticals: [ Monoclonal antibodies for medical or veterinary purposes, namely, for oncological, viral, infectious, endocrine, metabolic, neurological, cardiovascular, hematological, cardiopulmonary, respiratory, musculoskeletal, renal, hepatological, gastrointestinal, genitourinary, ophthalmic, dermatological, and immune system related diseases and disorders; peptides and proteins for medical or veterinary purposes, namely, for oncological, viral, infectious, endocrine, metabolic, neurological, cardiovascular, hematological, cardiopulmonary, respiratory, musculoskeletal, renal, hepatological, gastrointestinal, genitourinary, ophthalmic, dermatological, and immune system related diseases and disorders; biological and chemical preparations and reagents for medical or veterinary purposes, namely, for oncological, viral, infectious, endocrine, metabolic, neurological, cardiovascular, hematological, cardiopulmonary, respiratory, musculoskeletal, renal, hepatological, gastrointestinal, genitourinary, ophthalmic, dermatological, and immune system related diseases and disorders; medicines for human purposes, namely, for oncological, viral, infectious, endocrine, metabolic, neurological, cardiovascular, hematological, cardiopulmonary, respiratory, musculoskeletal, renal, hepatological, gastrointestinal, genitourinary, ophthalmic, dermatological, and immune system related diseases and disorders; medicines for dental purposes, namely, for infectious diseases, neurological diseases or inflammatory diseases; medicines for veterinary purposes, namely, for oncological, viral, infectious, endocrine, metabolic, neurological, cardiovascular, hematological, cardiopulmonary, respiratory, musculoskeletal, renal, hepatological, gastrointestinal, genitourinary, ophthalmic, dermatological, and immune system related diseases and disorders; medicinal preparations, namely, for oncological, viral, infectious, endocrine, metabolic, neurological, cardiovascular, hematological, cardiopulmonary, respiratory, musculoskeletal, renal, hepatological, gastrointestinal, genitourinary, ophthalmic, dermatological, and immune system related diseases and disorders; living cells for manufacturing monoclonal antibodies used for medical purposes; cell lines for manufacturing monoclonal antibodies used for medical purposes; living cells for manufacturing monoclonal antibodies used for veterinary purposes; cell lines for manufacturing monoclonal antibodies used for veterinary purposes; biological tissue cultures for medical purposes, namely, for cultivating living cells or cell lines used for manufacturing monoclonal antibodies; surgical implants comprised of living tissues; biological implants, namely, a vital processed human or animal connective tissue; disinfectants for hygiene purposes; sanitary sterilising preparations; biocides; preparations for destroying vermin ]
- Class 042 — Scientific and technological services: [ Research, product development and quality control services in the field of proteins, antibodies, microorganisms and cells, and consultancy relating thereto; research and development services in the field of antibody technology; biomedical research services; design and development of medical technology; research and development in the field of biotechnology; pharmaceutical research and development; conducting clinical trials for others in the field of pharmaceutical products; clinical trials for others; technical project studies in the field of monoclonal antibodies for medical or veterinary purposes and pharmaceutical products; technical research in the field of monoclonal antibodies for medical or veterinary purposes and pharmaceutical products; technical project planning in the field of monoclonal antibodies for medical or veterinary purposes and pharmaceutical products; research and development of new products for others; design and development of computer software for use with medical technology; software design and development; providing temporary use of non-downloadable business software; rental of computer software; cloud computing featuring software used for development of monoclonal antibodies for medical or veterinary purposes and pharmaceutical products ] * Research, product development and quality control services in the field of proteins, antibodies, microorganisms and cells, and consultancy relating thereto; research and development services in the field of antibody technology; biomedical research services; [ design and development of medical technology; ] research and development in the field of biotechnology; pharmaceutical research and development; [ conducting clinical trials for others in the field of pharmaceutical products; clinical trials for others; ] technical project studies in the field of monoclonal antibodies for medical [ or veterinary ] purposes and pharmaceutical products; technical research in the field of monoclonal antibodies for medical [ or veterinary ] purposes and pharmaceutical products; technical project planning in the field of monoclonal antibodies for medical [ or veterinary ] purposes and pharmaceutical products; research and development of new products for others [ ; design and development of computer software for use in research and development of monoclonal antibodies for medical or veterinary purposes and monoclonal antibody-based biopharmaceuticals; providing temporary use of non-downloadable business software for use in research and development of monoclonal antibodies for medical or veterinary purposes and monoclonal antibody-based biopharmaceuticals; rental of computer software for use in research and development of monoclonal antibodies for medical or veterinary purposes and monoclonal antibody-based biopharmaceuticals; cloud computing featuring software for use in research and development of monoclonal antibodies for medical or veterinary purposes and monoclonal antibody-based biopharmaceuticals * ]
Owner
- Chiome Bioscience Inc., Tokyo, JP
- Chiome Bioscience Inc., Tokyo, JP
- Chiome Bioscience Inc., Tokyo, JP
Prosecution history
- 15 Feb 2026 — COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
- 24 Apr 2025 — INTERNATIONAL REGISTRATION RENEWED
- 18 Apr 2025 — NEW REPRESENTATIVE AT IB RECEIVED
- 01 Apr 2024 — PARTIAL INVALIDATION PROCESSED BY THE IB
- 26 Feb 2024 — PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
- 26 Feb 2024 — INVALIDATION PROCESSED
- 10 Feb 2024 — PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
- 10 Jun 2023 — NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
- 10 Jun 2023 — REGISTERED - PARTIAL SEC 71 ACCEPTED
- 29 May 2023 — CASE ASSIGNED TO POST REGISTRATION PARALEGAL
- 15 Nov 2022 — TEAS SECTION 71 RECEIVED
- 14 Feb 2022 — COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
- 07 Mar 2018 — INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE
- 23 Feb 2018 — PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
- 28 Oct 2017 — FINAL DECISION TRANSACTION PROCESSED BY IB